Certara is transforming pediatric drug development with innovative modeling, simulation, and regulatory strategies. Our unique Pediatric MIDD approach integrates cutting-edge biosimulation with regulatory science, enabling the design of pediatric programs that meet global regulatory standards and ensure safe, effective medicines for children. With over 100 successful pediatric programs in our portfolio, we provide unmatched expertise in addressing challenges such as small populations, research burden, and physiological differences across age groups.
小児用医薬品開発
Advancing pediatric drug development with Certara
Innovative, evidence-based solutions for faster access to life-saving medicines for children.
Learn more about our Pediatric Drug Development Services
Comprehensive pediatric drug development support
Strategic planning
Create robust pediatric study plans (PSPs) and pediatric investigation plans (PIPs) tailored to regulatory requirements.
Innovative modeling
Leverage PK, PD, and disease progression models to optimize dosing and efficacy.
規制対応の専門知識
Navigate complex pediatric regulatory landscapes with expert guidance.
Comprehensive services
End-to-end support, from juvenile toxicology to real-world evidence integration.
Certara’s unique approach to pediatric drug development
Explore our pediatric drug development solutions
臨床薬理学
Strategies tailored for pediatric populations.
ファーマコメトリクス
Quantitative insights for informed pediatric trial designs.
薬事関連コンサルティング
Expert guidance for PIP and PSP submissions.
若年性毒性学
Ensuring the safety of pediatric therapies.
Real-world evidence
Data-driven insights from pediatric populations.
Meet the visionaries driving pediatric success
1 / 4
エキスパート
Amy Cheung, PhD
サターラ医薬品開発ソリューション担当副社長
Dr. Cheung leads pediatric pharmacometric strategies, with expertise in PK/PD modeling and regulatory planning.
専門家に相談する
2 / 4
エキスパート
Justin Hay, PhD
Senior Director, Clinical Pharmacology and Translational Medicine, Certara Drug Development Solutions
Dr. Hay has over 25 years of clinical pharmacology experience, previously working as a clinical pharmacology assessor of the MHRA (UK) and EMA.
専門家に相談する
3 / 4
エキスパート
Eva Berglund, PhD
Director, Clinical Pharmacology and Regulatory Strategy, Certara Drug Development Solutions
Dr. Berglund has over 12 years of experience working with all types of molecules in marketing applications, clinical trials and scientific advice procedures in the EMA.
専門家に相談する
4 / 4
エキスパート
Trevor Johnson, PhD
主任科学者
Dr. Johnson develops cutting-edge pediatric software for dose predictions and drug response analysis.
専門家に相談するDiscover more insights
全て見るPartner with Certara for pediatric drug development
Certara is your partner in overcoming pediatric drug development challenges and accelerating access to life-saving medicines for children. With advanced biosimulation tools, regulatory expertise, and a proven team, we deliver solutions that meet and exceed expectations.
Expertise in over 15 therapeutic areas.
Proven track record with more than 100 pediatric programs.
Industry-leading tools like Simcyp™ Pediatric PBPK Simulator.
サターラへのお問合せ
Explore our comprehensive solutions
よくある質問
What is the RACE for Children Act?
The RACE for Children Act mandates iPSP submissions for oncology drugs targeting pediatric cancers.
How does Certara ensure regulatory compliance?
Certara’s team provides expert guidance on PIP/PSP submissions and regulatory interactions with FDA and EMA.
What tools does Certara use in pediatric drug development?
The Simcyp™ Pediatric PBPK Simulator is a key tool used for modeling and predicting drug performance.
